{"title":"Keytruda","description":"","products":[{"product_id":"keytruda","title":"Keytruda (Pembrolizumab)","description":"\u003cp\u003e\u003cspan\u003eKeytruda (Pembrolizumab) is an innovative immunotherapy treatment designed to enhance the body's immune response against cancer. Approved for various types of cancer, including melanoma, lung cancer, and more, Keytruda works by blocking the PD-1 pathway, allowing immune cells to effectively target and destroy cancer cells. With its proven efficacy and safety profile, Keytruda offers hope for patients seeking advanced cancer treatment options.\u003c\/span\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003csection class=\"overview\"\u003e\n\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eKeytruda (Pembrolizumab) is an immunotherapy medication used to treat various types of cancer by enhancing the body's immune response against cancer cells. It is a monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) pathway, allowing T-cells to detect and attack cancer more effectively.\u003c\/p\u003e\n\u003c\/section\u003e\n\u003csection class=\"benefits\"\u003e\n\u003ch2\u003eBenefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eEffective in treating multiple cancer types, including melanoma, lung cancer, and more.\u003c\/li\u003e\n\u003cli\u003eHelps the immune system recognize and fight cancer cells.\u003c\/li\u003e\n\u003cli\u003eCan provide durable responses in some patients.\u003c\/li\u003e\n\u003cli\u003eAdministered via intravenous infusion, allowing for direct delivery into the bloodstream.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/section\u003e\n\u003csection class=\"dosage\"\u003e\n\u003ch2\u003eDosage\u003c\/h2\u003e\n\u003cp\u003eThe dosage of Keytruda is determined by a healthcare professional based on the patient's specific condition and response to treatment. It is typically administered every 3 weeks. Patients should follow the prescribed treatment plan and attend all scheduled appointments.\u003c\/p\u003e\n\u003c\/section\u003e\n\u003csection class=\"side-effects\"\u003e\n\u003ch2\u003eSide Effects\u003c\/h2\u003e\n\u003cp\u003eCommon side effects of Keytruda may include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFatigue\u003c\/li\u003e\n\u003cli\u003eCough\u003c\/li\u003e\n\u003cli\u003eRash\u003c\/li\u003e\n\u003cli\u003eItching\u003c\/li\u003e\n\u003cli\u003eNausea\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSerious side effects can occur and should be reported to a healthcare provider immediately, including symptoms of an allergic reaction, lung problems, liver problems, and severe skin reactions.\u003c\/p\u003e\n\u003c\/section\u003e\n\u003csection class=\"faqs\"\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eFAQs\u003c\/h2\u003e\n\u003ch3\u003eWhat is Keytruda used for?\u003c\/h3\u003e\n\u003cp\u003eKeytruda is used to treat various cancers, including melanoma, non-small cell lung cancer, and other malignancies that express PD-L1.\u003c\/p\u003e\n\u003ch3\u003eHow is Keytruda administered?\u003c\/h3\u003e\n\u003cp\u003eKeytruda is administered via intravenous infusion by a healthcare professional.\u003c\/p\u003e\n\u003ch3\u003eWhat should I do if I miss a dose?\u003c\/h3\u003e\n\u003cp\u003eIf you miss a dose, contact your healthcare provider for instructions on when to reschedule your treatment.\u003c\/p\u003e\n\u003ch3\u003eCan Keytruda be used in combination with other treatments?\u003c\/h3\u003e\n\u003cp\u003eYes, Keytruda may be used in combination with other therapies depending on the specific cancer type and treatment plan.\u003c\/p\u003e\n\u003c\/section\u003e","brand":"CTJOPTICAL","offers":[{"title":"100mg","offer_id":50942207852850,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true},{"title":"200mg","offer_id":50942207885618,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0753\/4664\/1202\/files\/ctj_11.jpg?v=1772426695"},{"product_id":"keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-merck-395mg","title":"Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph, Merck) 395mg","description":"\u003cp\u003e\u003cstrong\u003eKEYTRUDA QLEX \u003cspan\u003e(pembrolizumab and berahyaluronidase alfa-pmph, \u003c\/span\u003e\u003ca href=\"https:\/\/respiratory-therapy.com\/tag\/merck\/\"\u003eMerck\u003c\/a\u003e\u003cspan\u003e) i\u003c\/span\u003es Approved for Use in Adult Patients Across Solid Tumor Indications for KEYTRUDA—Whether Alone or in Combination With Other Therapies\u003c\/strong\u003e\u003c\/p\u003e\n\u003cheader\u003e\n\u003ch3 class=\"Heading__H7-sc-1aw7hbk-6 styled__InformationItemLabel-sc-7thute-1 jfUObE iTiAGm\"\u003eAdvanced Melanoma or Adjuvant Therapy for Melanoma\u003c\/h3\u003e\n\u003c\/header\u003e\n\u003cdiv class=\"IndicationsList__IndicationsListContent-sc-aefdy2-0 eGdhAK\"\u003e\n\u003cp\u003eKEYTRUDA and KEYTRUDA QLEX are each indicated for the treatment of adult patients with unresectable or metastatic melanoma.\u003c\/p\u003e\n\u003cp\u003eKEYTRUDA and KEYTRUDA QLEX are each indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with stage IIB, IIC, or III melanoma following complete resection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003e\u003cspan class=\"Text__Caption-sc-1yxudd0-2 qlex__StyledCaption-sc-uhvyz7-13 cARBqm debAuo\"\u003eOne such indication is for the adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn another significant step toward making cancer treatment more convenient and accessible for patients, the U.S. Food and Drug Administration (FDA) has approved a \u003c\/span\u003e\u003cstrong\u003enew\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eunder-the-skin (subcutaneous) formulation\u003c\/strong\u003e\u003cspan\u003e of the widely used immunotherapy Keytruda® (pembrolizumab) for adolescent and adult patients with \u003c\/span\u003e\u003ca href=\"https:\/\/www.cancerresearch.org\/blog\/fighting-colorectal-cancer-with-immunotherapy-what-you-need-to-know\"\u003emultiple types of solid tumors\u003c\/a\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eTraditionally, Keytruda has been administered directly into the vein via an intravenous (IV) infusion, which takes approximately 30 minutes. Now, some patients can receive the\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003every same treatment\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ethrough a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003equick under-the-skin injection\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ethat can be completed in as little as\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eone minute.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKeytruda works by blocking PD-1, a key immune checkpoint protein that cancers use to evade the immune system. Since its initial approval in 2014, Keytruda has revolutionized cancer care, with\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e\u003ca href=\"https:\/\/www.cancerresearch.org\/blog\/keytruda-receives-40th-fda-approval\"\u003eover 40 FDA approvals across a number of tumor types\u003c\/a\u003e\u003c\/strong\u003e, benefiting a broad range of patients.\u003c\/p\u003e\n\u003cp\u003eWhile lifesaving, IV infusions can create significant logistical challenges: patients must travel to infusion centers, adjust work and\/or family schedules, and commit time to the infusion itself. Such hurdles can chip away at patients’ quality of life, making an already difficult journey even more challenging.\u003c\/p\u003e\n\u003cp\u003eThe new\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003esubcutaneous (SC) version of Keytruda\u003c\/strong\u003e, called\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eKeytruda Qlex\u003c\/em\u003e, changes that experience. This shorter, more convenient procedure can be delivered in a wider variety of healthcare settings — from major hospitals to local community clinics — reducing both time and travel burdens.\u003c\/p\u003e\n\u003cp\u003eFor patients, this means\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003emore flexibility, less disruption, and more time for life outside of cancer care\u003c\/strong\u003e. By easing the treatment process,\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.cancerresearch.org\/blog\/introducing-the-cri-cancer-immunotherapy-insights-impact-report\"\u003ethis new injectable option allows patients to focus on living, rather than scheduling their lives around infusions\u003c\/a\u003e.\u003c\/p\u003e","brand":"CTJOPTICAL","offers":[{"title":"395mg","offer_id":50942560305458,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0753\/4664\/1202\/files\/ctj_25_d436c4b0-dd7d-422a-90c5-28b88c5892fe.jpg?v=1772429656"},{"product_id":"keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-merck-790mg","title":"Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph, Merck) 790mg","description":"\u003cp\u003e\u003cstrong\u003eKEYTRUDA QLEX \u003cspan\u003e(pembrolizumab and berahyaluronidase alfa-pmph, \u003c\/span\u003e\u003ca href=\"https:\/\/respiratory-therapy.com\/tag\/merck\/\"\u003eMerck\u003c\/a\u003e\u003cspan\u003e) i\u003c\/span\u003es Approved for Use in Adult Patients Across Solid Tumor Indications for KEYTRUDA—Whether Alone or in Combination With Other Therapies\u003c\/strong\u003e\u003c\/p\u003e\n\u003cheader\u003e\n\u003ch3 class=\"Heading__H7-sc-1aw7hbk-6 styled__InformationItemLabel-sc-7thute-1 jfUObE iTiAGm\"\u003eAdvanced Melanoma or Adjuvant Therapy for Melanoma\u003c\/h3\u003e\n\u003c\/header\u003e\n\u003cdiv class=\"IndicationsList__IndicationsListContent-sc-aefdy2-0 eGdhAK\"\u003e\n\u003cp\u003eKEYTRUDA and KEYTRUDA QLEX are each indicated for the treatment of adult patients with unresectable or metastatic melanoma.\u003c\/p\u003e\n\u003cp\u003eKEYTRUDA and KEYTRUDA QLEX are each indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with stage IIB, IIC, or III melanoma following complete resection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003e\u003cspan class=\"Text__Caption-sc-1yxudd0-2 qlex__StyledCaption-sc-uhvyz7-13 cARBqm debAuo\"\u003eOne such indication is for the adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn another significant step toward making cancer treatment more convenient and accessible for patients, the U.S. Food and Drug Administration (FDA) has approved a \u003c\/span\u003e\u003cstrong\u003enew\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eunder-the-skin (subcutaneous) formulation\u003c\/strong\u003e\u003cspan\u003e of the widely used immunotherapy Keytruda® (pembrolizumab) for adolescent and adult patients with \u003c\/span\u003e\u003ca href=\"https:\/\/www.cancerresearch.org\/blog\/fighting-colorectal-cancer-with-immunotherapy-what-you-need-to-know\"\u003emultiple types of solid tumors\u003c\/a\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eTraditionally, Keytruda has been administered directly into the vein via an intravenous (IV) infusion, which takes approximately 30 minutes. Now, some patients can receive the\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003every same treatment\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ethrough a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003equick under-the-skin injection\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ethat can be completed in as little as\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eone minute.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKeytruda works by blocking PD-1, a key immune checkpoint protein that cancers use to evade the immune system. Since its initial approval in 2014, Keytruda has revolutionized cancer care, with\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e\u003ca href=\"https:\/\/www.cancerresearch.org\/blog\/keytruda-receives-40th-fda-approval\"\u003eover 40 FDA approvals across a number of tumor types\u003c\/a\u003e\u003c\/strong\u003e, benefiting a broad range of patients.\u003c\/p\u003e\n\u003cp\u003eWhile lifesaving, IV infusions can create significant logistical challenges: patients must travel to infusion centers, adjust work and\/or family schedules, and commit time to the infusion itself. Such hurdles can chip away at patients’ quality of life, making an already difficult journey even more challenging.\u003c\/p\u003e\n\u003cp\u003eThe new\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003esubcutaneous (SC) version of Keytruda\u003c\/strong\u003e, called\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eKeytruda Qlex\u003c\/em\u003e, changes that experience. This shorter, more convenient procedure can be delivered in a wider variety of healthcare settings — from major hospitals to local community clinics — reducing both time and travel burdens.\u003c\/p\u003e\n\u003cp\u003eFor patients, this means\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003emore flexibility, less disruption, and more time for life outside of cancer care\u003c\/strong\u003e. By easing the treatment process,\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.cancerresearch.org\/blog\/introducing-the-cri-cancer-immunotherapy-insights-impact-report\"\u003ethis new injectable option allows patients to focus on living, rather than scheduling their lives around infusions\u003c\/a\u003e.\u003c\/p\u003e","brand":"CTJOPTICAL","offers":[{"title":"790mg","offer_id":50942567907634,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0753\/4664\/1202\/files\/ctj_25_d436c4b0-dd7d-422a-90c5-28b88c5892fe.jpg?v=1772429656"}],"url":"https:\/\/ctjopticals.com\/collections\/keytruda.oembed","provider":"CTJOPTICALS","version":"1.0","type":"link"}